1. Home
  2. NCPL vs XBIO Comparison

NCPL vs XBIO Comparison

Compare NCPL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCPL

Netcapital Inc.

HOLD

Current Price

$0.70

Market Cap

7.1M

Sector

Finance

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.07

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCPL
XBIO
Founded
1984
N/A
Country
United States
United States
Employees
20
2
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
6.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCPL
XBIO
Price
$0.70
$3.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4M
14.4K
Earning Date
03-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$739.37
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$1.90
52 Week High
$8.75
$13.93

Technical Indicators

Market Signals
Indicator
NCPL
XBIO
Relative Strength Index (RSI) 46.11 38.44
Support Level $0.59 $2.74
Resistance Level $0.84 $3.44
Average True Range (ATR) 0.13 0.17
MACD -0.06 -0.03
Stochastic Oscillator 13.35 0.00

Price Performance

Historical Comparison
NCPL
XBIO

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: